MINERALYS THERAPEUTICS, INC.

Highlights Mineralys Therapeutics, Inc.

Equities

MLYS

US6031701013

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
12.2 ^USD	-0.25%		-6.15%	+41.86%

05-16	Transcript : Mineralys Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 05:01 PM
05-09	Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Mineralys Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Mineralys Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
North American Morning Briefing : Investors -2-	03-21	DJ
Mineralys Therapeutics, Inc. Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension	12-22	CI
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023	11-11	CI
Mineralys Therapeutics, Inc Presents Data from the Target-HTN Phase 2 Trial That Further Defines an Endotype-Specific Targeted Approach for Treating Uncontrolled or Resistant Hypertension with Lorundrostat	11-11	CI
Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Mineralys Therapeutics, Inc. Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting	11-02	CI
Mineralys Therapeutics, Inc. Announces Jama Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension	23-09-10	CI
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session At 2023 Aha Hypertension Scientific Sessions	23-09-10	CI
Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Mineralys Therapeutics, Inc. Doses the First Patient in the Advanceance-Htn Pivotal Trial	23-05-02	CI
Mineralys Therapeutics Q4 Loss Widens; Shares Decline After-Hours	23-03-15	MT
Mineralys Therapeutics Reports Positive Lorundrostat Results in Reducing Hypertension in Phase 2 Trial	23-03-06	MT
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC	23-03-04	CI
Mineralys Therapeutics Prices IPO at $16 per Share	23-02-10	MT
Mineralys Therapeutics, Inc. has completed an IPO in the amount of $192 million.	23-02-10	CI
Mineralys Therapeutics, Inc. has filed an IPO in the amount of $100 million.	23-01-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer